Navigation Links
Gen-Probe Reports Financial Results for the Second Quarter of 2011
Date:7/28/2011

p>

(non-GAAP)

Current

Guidance

(GAAP)

Previous

Guidance

(GAAP)Total revenues

$575 to $590 million

$570 to $595 million

$575 to $590 million

$570 to $595 millionProduct gross margins

69% to 70%

68% to 69.5%

69% to 70%

68% to 69.5%Acquisition-related amortization and other transaction expense

N/A

N/A

$15 million

$13 to $14 millionOperating margin

27% to 29%

27% to 29%

24.5% to 26.5%

25% to 27%Tax rate

32% to 33%

32% to 33%

32% to 33%

32% to 33%Diluted shares

49 million

48 to 49 million

49 million

48 to 49 millionEPS

$2.28 to $2.37

$2.28 to $2.40

$2.06 to $2.15

$2.06 to $2.20Notes on PresentationIn this news release, all per share amounts are calculated on a fully diluted basis.  Some totals may not foot due to rounding.  Certain prior year amounts have been reclassified to conform to the current year presentation.  Estimates of "constant currency" results exclude currency fluctuations associated with revenue from GTI, which was not part of Gen-Probe in the second quarter of 2010.

About Non-GAAP Financial MeasuresGen-Probe's management believes that non-GAAP financial measures provide meaningful supplemental information regarding the Company's performance by excluding certain expenses that may not be indicative of core business results.  To supplement the Company's financial results for the second quarter of 2011 and its updated 2011 financial guidance, in each case presented in accordance with GAAP, Gen-Probe uses the following financial measures defined as non-GAAP by the SEC: non-GAAP net income, non-GAAP gross margin, non-GAAP marketing and sales expenses, non-GAAP G&A expenses, non-GAAP operating profit, non-GAAP income tax rate, and non-GAAP EPS.  Gen-Probe's management does not, nor does
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Gen-Probe to Webcast Presentation at the Thomas Weisel Partners Healthcare Conference 2008
2. Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
3. Gen-Probe to Webcast Presentation at the Bank of America 38th Annual Investment Conference
4. Gen-Probe to Webcast Presentation at the UBS Global Life Sciences Conference
5. Gen-Probe to Webcast Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference
6. Promising Clinical Data on Gen-Probes APTIMA(R) HPV Test Presented at Major European Medical Meeting
7. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2008 Earnings Conference Call
8. Eric Lai Joins Gen-Probe as Senior Vice President, Research and Development
9. Gen-Probe Borrows $170 Million Under New Line of Credit
10. Gen-Probe to Webcast Two Upcoming Investor Presentations
11. Gen-Probe Completes Acquisition of Tepnel Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... CHICAGO , May 27 Celsis International, ... its Drug Master Files with the U.S. Food & Drug Administration (FDA) ... solutions and finished goods on the Celsis system. , ... "A growing number of our Rapid Detection customers ...
... Genetics Corporation announced today treatment of the first patient in a nationwide ... have successfully undergone pancreatic surgical resection. , ... "This pivotal study represents one of the largest Phase ... the United States ," said Charles Link , M.D., chairman and ...
... , May 27, 2010 , ... - New Trial Results on ExoSeal(TM) Vascular Closure Device Support its,Clinical ... Cordis ... launch of the,ExoSeal(TM) Vascular Closure Device. ExoSeal(TM) incorporates a number of new,advances in technology ...
Cached Biology Technology:Celsis Rapid Detection's Updated Drug Master Files (DMFs) Accepted by FDA 2NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer 2NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer 3NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer 4CORDIS Launches ExoSeal(TM) Vascular Closure Device 2CORDIS Launches ExoSeal(TM) Vascular Closure Device 3CORDIS Launches ExoSeal(TM) Vascular Closure Device 4
(Date:12/10/2014)... , Dec. 9, 2014 CIE San Diego ... that provides the connective tissue that enhances care coordination ... to easily share client-level information; earned a second $1 ... to organizations serving seniors aging in community and; will ... on December 11 th 4-6p. CIE ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... climate change, a new book by Claire L. Parkinson, ... Center in Greenbelt, Md., can provide some answers. ... Beware the Big Fix," will be published this week ... warming is such a big deal, summarizes 4.6 billion ...
... the Carnegie Institution,s Department of Global Ecology, is among ... the humanities and the arts, business, public affairs, and ... new class of members of the American Academy of ... most prestigious honorary societies, cited Field for his research ...
... pain (or lumbago) is a common ailment often triggered by something ... to remedy the situation? An exercise machine designed specifically for back ... in the Journal of the American College of Sports Medicine ... help the development and endurance of back muscles, you must focus ...
Cached Biology News:NASA scientist publishes new book: 'Coming Climate Crisis? Consider the Past, Beware the Big Fix' 2Carnegie's Chris Field elected to American Academy of Arts & Sciences 2Exercise therapy for low back pain 2